Home

  • Order to parcel locker

    Order to parcel locker

  • easy pay

    easy pay
  • Reduced price
Cancer Chemotherapy and Biotherapy

See next edition:

Cancer Chemotherapy, Immunotherapy, and Biotherapy
Cancer Chemotherapy, Immunotherapy, and Biotherapy

Cancer Chemotherapy and Biotherapy

Principles and Practice

9781605474311
1,127.70 zł
1,014.93 zł Save 112.77 zł Tax included
Lowest price within 30 days before promotion: 1,014.93 zł
Quantity
Product unavailable
Out of print

  Delivery policy

Choose Paczkomat Inpost, Orlen Paczka, DPD or Poczta Polska. Click for more details

  Security policy

Pay with a quick bank transfer, payment card or cash on delivery. Click for more details

  Return policy

If you are a consumer, you can return the goods within 14 days. Click for more details

Description
Updated to include the newest drugs and those currently in development, Cancer Chemotherapy and Biotherapy, Fifth Edition is a comprehensive reference on the preclinical and clinical pharmacology of anticancer agents. Organized by drug class, the book provides the latest information on all drugs and biological agents—their mechanisms of action, interactions with other agents, toxicities, side effects, and mechanisms of resistance. Chapters emphasize pharmacology and mechanisms of action at the molecular and cellular levels, followed by clinical activity and toxicity, both acute and delayed. The authors explain the rationale for use of drugs in specific schedules and combinations and offer guidelines for dose adjustment in particular situations.

This editions introduction includes timely information on general strategies for drug usage, the science of drug discovery and development, economic and regulatory aspects of cancer drug development, and principles of pharmacokinetics. Eight new chapters have been added and more than twenty have been significantly revised.

A companion website includes the fully searchable text and an image bank.
Product Details
LWW
47605
9781605474311
9781605474311

Data sheet

Publication date
2010
Issue number
5
Cover
hard cover
Pages count
848
Dimensions (mm)
5403 x 7016
Weight (g)
977310
  • Section 1: BASIC PRINCIPLES OF CANCER TREATMENT

    1: Clinical Strategies for Cancer Treatment: The Role of Drugs
    Bruce Chabner

    2: Target Identification and Drug Discovery
    Ed Sausville

    3: Clinical Drug Development and Approval for Marketing
    Thomas Roberts

    4: Principles of Pharmacokinetics
    Jerry Collins

    5: Special Aspects of Brain Tumor Chemotherapy
    Jeffrey Supko & Tracy Batchelor

    6: Pharmacogenetics
    Howard McLeod

    7: Barriers to Drug Delivery
    Brendan Curti

    Section 2: CYTOTOXIC AGENTS

    8: Antifolates
    Carmen Allegra & Bruce Chabner

    9: Fluoro-pyrimidines
    David Ryan, Bruce Chabner & Ray Wadlow

    10: Cytidine Analogues
    David Ryan & Bruce Chabner

    11: Purine Analogues
    Ken Hande

    12: Hydroxyurea
    Bruce Chabner

    13: Antimitotic Drugs
    Ross Donehower

    14: Alkylating Agents (Including Methylating Agents)
    Stan Gerson & Henry Friedman

    15: Platinum Analogues
    Ed Reed

    16: Antitumor Antibiotics (Including Bleomycin)
    Bruce Chabner

    17: Topoisomerase I Inhibitors
    Alex Spaareboom & William Zamboni

    18: Topoisomerase II Inhibitors: Anthracyclines
    Jim Doroshow

    19: Topoisomerase II Inhibitors: Etoposide, Teniposide
    George Hartman & Yves Pommier

    20: L-Asparaginase
    Bruce Chabner & Alison Friedmann

    Section 3: MOLECULARLY TARGETED THERAPIES

    21: Proteosome Inhibitors
    Orhan Sezar

    22: HDAC Inhibitors
    Susan Bates

    23: Differentiating Agents (Retinoids)
    Bruce Chabner

    24: Arsenic Trioxide
    Bruce Chabner

    25: Monoclonal Antibodies: Discovery & Development
    David Scheinberg

    26: Anti-angiogenic Agents (Including MonAB)
    William Gradishar & Kari Wisinski

    27: Anti-EGFR Therapies (Including MonAB)
    Lecia Sequist & Joel Neal

    28: Anti-her 2 Therapies
    Eric Winer

    29: Intracellular Signal Inhibitors (bcr-abl)
    Bruce Chabner & Jeffrey Barnes

    30: Signal Transduction Inhibitors in Development
    Jeff Clark

    31: Inhibitors of the PI3k Pathway & Mitotic Kinase
    Percy Ivy

    Section 4: IMMUNOLOGIC AGENTS

    32: Interferon and Cytokines
    David McDermott

    33: Vaccines
    Robert G. Fenton

    34: Adoptive Cellular Therapies
    Cassian Yee

    35: Immuno-modulatory Drugs (IMIDS, Anti-CTLA4)
    Paul Richardson et al.

    Section 5: HORMONAL THERAPY

    36: Hormonal Therapy of Breast Cancer
    Beverly Moy & Paul Goss

    37: GNRH Agonists and Anti-Androgens
    Richard Lee

    Section 6: SUPPORTIVE CARE

    38: Pain Management in Cancer Patients
    Paul Glare

    39: Colony Stimulating Factors
    Gary Lyman

    40: Anti-nausea Medications
    Ian Olver

    41: Bone Loss Modulators
    Matthew Smith

    42: Intravenous Access and Catheter Management
    Rachel Rosovsky

    Section 7: SURVIVORSHIP

    43: Monitoring for Late Side Effects of Chemotherapy
    Richard Schilsky, Charles Erlichman & Brian Costello

See next edition:

Cancer Chemotherapy, Immunotherapy, and Biotherapy
Cancer Chemotherapy, Immunotherapy, and Biotherapy
Comments (0)

  • Frequently purchased together

    No products available